Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: 'It hurts to be on the cutting edge'.

Belkacemi Y; Gligorov J

首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: 'It hurts to be on the cutting edge'.

【24h】

Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: 'It hurts to be on the cutting edge'.

机译：并发曲妥珠单抗-HER2阳性乳腺癌的内部乳腺照射：“处于最前沿很痛苦”。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In regard to Richard Shaffer et al.Re: Shaffer R, Tyldesley S, Rolles M, Chia S, Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single-institution study. Radiother Oncol 2009;90:122-6.In the above-noted report, Shaffer et al. have suggested that "there was no excess of acute cardiotoxicity observed with the combination of left-sided internal mammary chain (IMC) irradiation and concurrent trastuzumab" [1].

机译：关于Richard Shaffer等人，Re：Shaffer R，Tyldesley S，Rolles M，Chia S，Mohamed I.同时曲妥珠单抗和放疗（包括内部乳腺链结）的急性心脏毒性：一项回顾性单机构研究。 Radiother Oncol 2009; 90：122-6。在上述报告中，Shaffer等人。曾提出“左侧乳腺内链（IMC）照射与并发曲妥珠单抗联合使用不会观察到过量的急性心脏毒性” [1]。

著录项

来源
《Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology》 |2010年第1期|共3页
作者
Belkacemi Y; Gligorov J;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge". [J] . Belkacemi Y, Gligorov J Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology . 2010,第1期

机译：并发曲妥珠单抗-HER2阳性乳腺癌的内部乳腺照射：“处于最前沿很痛苦”。
2. RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial [J] . Belkacemi Yazid, Kuten Abraham Journal of the National Cancer Institute . 2018,第5期

机译：Re：哺乳期哺乳期乳腺癌后辐照辐照治疗早期Her2阳性乳腺癌：从ALTTO试验中分析的结果
3. RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial [J] . Belkacemi Yazid, Kuten Abraham Journal of the National Cancer Institute . 2018,第5期

机译：Re：哺乳期哺乳期乳腺癌后辐照辐照治疗早期Her2阳性乳腺癌：从ALTTO试验中分析的结果
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Analysis of the oncogenic cooperation between mutp53 and HER2 to propose mutp53 as a biomarker for HER2-positive breast cancer. [D] . Russo, Amanda Deanna. 2014

机译：分析mutp53和HER2之间的致癌合作，提出mutp53作为HER2阳性乳腺癌的生物标志物。
6. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial [O] . Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, -1

机译：早期HER2阳性乳腺癌的保乳手术后的区域淋巴结照射：ALTTO试验的亚分析结果
7. p63 suppresses the ability of pregnancy-identified mammary epithelial cells (PIMECs) to drive HER2-positive breast cancer [O] . Christopher E. Eyermann, Jinyu Li, Evguenia M. Alexandrova 2021

机译：P63抑制妊娠鉴定的乳腺上皮细胞（PIMEC）驱动HER2阳性乳腺癌的能力

Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: 'It hurts to be on the cutting edge'.

摘要

著录项

相似文献

相关主题

期刊订阅